Imcivree has shown benefit in a Phase III trial in patients with acquired hypothalamic obesity, leading to 19.8% weight loss.

While pharma giants Novo Nordisk and Eli Lilly may have a solid hold on the obesity arena, Rhythm Pharmaceuticals is looking ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Rhythm Pharmaceuticals met phase 3 endpoint for treating hypothalamic obesity, with regulatory submissions planned for 2025.

Study results in a rare form of obesity could help the company expand use of Imcivree, which is approved for two genetically ...

Stifel analysts were bullish on the data, which showed a 16.5% drop in body-mass index among patients with damage to the ...

Rhythm Pharmaceuticals Inc.’s sales with Imcivree (setmelanotide) in weight management could exceed $1 billion by 2028 if hypothalamic obesity (HO) is added to the label of the drug, Oppenheimer ...

Rhythm Pharmaceuticals said on Monday that its experimental drug to treat a rare obesity disorder met the main goal in a late-stage trial.

The biotech’s drug, Imcivree, has FDA approvals for two rare forms of obesity. Preliminary data from a pivotal test in yet another type position the drug to continue Rhythm’s pipeline-in-a ...

The TRANSCEND trial evaluated the efficacy and safety of setmelanotide for the treatment of acquired hypothalamic obesity.